Global Retailer group OYSHO and Swiss apparel technology group X-BIONIC & X-SOCKS design a collection together / OYSHO by X-BIONIC I Once again, Fashion follows function
21.12.2020 15:14:22 CET | news aktuell GmbH | Pressemelding

Tordera, Spain/Wollerau,Switzerland, 21 December 2020 – OYSHO, part of one of the largest retail groups in the world and Swiss apparel technology group X-BIONIC launched an exclusive ski underwear collection, OYSHO by X-BIONIC.
Once again the Swiss think-tank, recent innovation award winner of the “Future made in Switzerland”, is revolutionising the sports industry with another global partnership. Expanding their footprint on the sports apparel market and branching into the fashion industry.
True to its style, X-BIONIC & X-SOCKS once again affirm that fashion follows function. The new collection composed of ski underwear and skisocks feature the patented technologies that have made the Swiss brand, the number 1 technological sports textile company in the world and the most innovative brand for 12 years in a row.
“By integrating our award winning, patented technologies into this collection for OYSHO, the OYSHO by X-BIONIC ski collection, we allow their customers to feel comfortable and to enjoy their winter sports regardless of the climate conditions. A feeling, unlike anything they have experienced before.” said Professor Dr. Bodo Lambertz, Founder of X-BIONIC.
This exclusive, limited-edition collection for OYSHO is only available at OYSHO.COM and at some of the most exclusive flag ship stores of the Spanish group distributed worldwide.
Bilder


Om news aktuell GmbH
X-BIONIC:
Our scientifically proven thermoregulation technology optimizes body core temperature allowing athletes to perform at their absolute best. With over 800 international patent registrations, over 600 awards and more than 1210 medals in international championships including olympics, X-BIONIC is the leader in technical sportswear and has been named the “Most Innovative Brand” twelve years in a row.
Følg pressemeldinger fra news aktuell GmbH
Registrer deg med din e-postadresse under for å få de nyeste sakene fra news aktuell GmbH på e-post fortløpende. Du kan melde deg av når som helst.
Siste pressemeldinger fra news aktuell GmbH
Webasto Air Top Pro 25: a new, exceptionally quiet parking heater for campers22.10.2026 13:52:44 CEST | Press release
Why should the camping season end just because summer is over? The colder months offer unique experiences—from skiing and snowshoeing to simply enjoying the winter landscape. To ensure your motorhome or campervan remains a comfortable retreat even in low temperatures, the right heating solution is crucial.
Polarise Launches Sovereign AI Cloud at NVIDIA GTC Berlin, Delivering Enterprise AI From Data Center to Application22.10.2026 10:00:00 CEST | Press release
With Polarise Rise and Polarise Drive, the German AI provider extends its own European AI Factories into a full-stack sovereign cloud
Democracy News Alliance: Fiscal strength doesn't guarantee public goods delivery, US study finds21.10.2026 09:55:20 CEST | Press release
New York/DNA - A newly released study of US state government performance found strong partisan and regional patterns within three pillars of governance: democratic accountability, state capacity and public goods provision. Yet, the US states’ outcomes differ in important ways from international comparisons, as the three governance dimensions show limited correlation, the researchers found.
agineo expands partnership with ServiceNow, launches AI Control Tower as a Service20.10.2026 13:06:01 CEST | Press release
New managed service provides transparency into the AI landscape and helps companies centrally manage AI, monitor risks and regulatory requirements, and highlight business benefits.
Grünenthal advances proprietary Nociceptin Receptor (NOP) Agonist into Phase II trial in acute pain20.10.2026 10:17:49 CEST | Press release
Potential first-in-class, selective nociceptin receptor (NOP) agonist that aims to provide safe, effective treatment for moderate to severe acute pain. Following successful Phase I results earlier this year demonstrating an excellent safety profile, the program has now progressed to Phase II. The randomized, double-blind, double-dummy, placebo- and active controlled, 2-part Phase II trial will evaluate the safety, tolerability and efficacy of this novel NOP agonist in patients post bunionectomy surgery. Grünenthal anticipates reporting results in early 2028.
I vårt presserom finner du alle våre siste pressemeldinger, kontaktpersoner, bilder, dokumenter og annen relevant informasjon om oss.
Besøk vårt presserom
